PolyNovo (ASX:PNV) Gets FDA nod for Pivotal Trial IDE, Share Price Jumps

  • November 13, 2020 02:13 PM AEDT
  • Kunal Sawhney
    Kunal Sawhney
    CEO Kunal Sawhney
    2781 Posts

    Kunal Sawhney is founder & CEO at Kalkine and is a richly experienced and accomplished financial professional with a wealth of knowledge in the Australian Equities Market. Kunal obtained a Master of Business Administration degree from University of T...

PolyNovo (ASX:PNV) Gets FDA nod for Pivotal Trial IDE, Share Price Jumps

Summary

  • ASX 200-listed PolyNovo Limited receives FDA green light for its BARDA supported pivotal trial IDE.
  • The Company is set to commence a clinical trial at 20 sites to recruit 150 patients.
  • Polynovo estimate recruitment will start early in the calendar year 2021.

ASX 200-listed healthcare player PolyNovo Limited (ASX:PNV) revealed on Friday that it had received the green light from US regulator FDA for the pivotal trial investigation device exemption (IDE).

The Australia-based medical device player is engaged in the development of innovative medical devices by utilising the patented Novosorb® technology. NovoSorb BTM is the first commercialised product by the Company.

Buoyed up by this significant announcement, the share price of PolyNovo saw an uptick of 4.642% to A$2.930 at AEST 11:34 AM. The market capitalisation of PolyNovo stood at A$1.85 billion.

PolyNovo to kick off clinical trial at 20 sites

The receiving of the FDA approval for pivotal trial IDE allows PolyNovo intends to begin patient recruitment after receiving further approval from the hospital Independent Review Boards (IRB) grant. Post the IRB approval, PolyNovo is expected to start a clinical trial at 20 sites to recruit 150 patients.

The Company mentioned that additional details of the sites and study including the finalised list of trial hospitals shall be published in due course.

Polynovo estimates recruitment to commence early in the calendar year 2021 and conclude around the end of the calendar year 2023. This clinical development is supported by a US$15 million funding from BARDA. PolyNovo has a research and development service providing agreement with BARDA that has been extended until August 2025.

Managing Director PolyNovo, Paul Brennan commented-

Source: Company announcement dated 13 November 2020

PolyNovo stated that successful completion of the pivotal trial will lead to a PMA application, leading to the use of platform of PNV for full-thickness acute burns.

Also, Pivotal trial completion may lead to BARDA acquiring a stockpile of NovoSorb BTM for disaster management.

Lately, PolyNovo also updated the market with its entry in Greece. On 2 November 2020, the Company announced the appointment of Biogenesys as its distribution partner in Greece.

ALSO READ: PolyNovo (ASX:PNV) Obtains Taiwanese FDA Green Light

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK